Gideon Koren1,2, Galia Norton3, Kira Radinsky3, Varda Shalev4,5. 1. Maccabi-Khan Institute of Research and Innovation, 4 Koifman St, 8th floor, 6812509, Tel Aviv, Israel. gidiup_2000@yahoo.com. 2. Tel Aviv University, Tel Aviv, Israel. gidiup_2000@yahoo.com. 3. Technion-Israel Institute of Technology, Haifa, Israel. 4. Maccabi-Khan Institute of Research and Innovation, 4 Koifman St, 8th floor, 6812509, Tel Aviv, Israel. 5. Tel Aviv University, Tel Aviv, Israel.
Abstract
BACKGROUND: Most patients with Parkinson's disease exhibit intracellular accumulation of the α-synuclein protein encoded by the α-synuclein gene. It was recently shown that β2-adrenoreceptor agonists downregulate this gene, decreasing the apparent risk of Parkinson's disease by up to 40%. In contrast, exposure to β-blocking drugs increases production of the α-synuclein protein. OBJECTIVE: The aim of this study was to examine whether chronic exposure to β-blockers is associated with an increased risk for Parkinson's disease. PATIENTS AND METHODS: From the electronic charts of Maccabi Health Services, we identified all patients receiving their first β-blocker treatment between 1998 and 2004, and followed them up, for a diagnosis of Parkinson's disease, between 2005 and 2016. We calculated the morbidity hazard of Parkinson's disease diagnosis in users of β-blockers compared with non-users, as well as users of angiotensin-converting enzyme (ACE) inhibitors for hypertension, after adjusting for sex, age, weight, smoking status, cholesterol levels and use of statins, employing the Cox proportional hazard model. We also conducted a Kaplan-Meier survival analysis. RESULTS: Overall, 145,098 patients received β-blockers, and 1,187,151 patients did not. The adjusted hazard ratio for Parkinson's disease among β-blocker users was 1.51 (95% confidence interval 1.28-1.77; p < 0.0001). In contrast, the Parkinson's disease morbidity hazard for patients receiving ACE inhibitors was no different than for the general population. The morbidity risk showed the effect of cumulative dose response with low threshold levels. CONCLUSIONS: Chronic use of β-blockers confers a time- and dose-dependent increased risk for Parkinson's disease. In view of the available alternatives for β-blockers, their chronic use should be carefully reconsidered.
BACKGROUND: Most patients with Parkinson's disease exhibit intracellular accumulation of the α-synuclein protein encoded by the α-synuclein gene. It was recently shown that β2-adrenoreceptor agonists downregulate this gene, decreasing the apparent risk of Parkinson's disease by up to 40%. In contrast, exposure to β-blocking drugs increases production of the α-synuclein protein. OBJECTIVE: The aim of this study was to examine whether chronic exposure to β-blockers is associated with an increased risk for Parkinson's disease. PATIENTS AND METHODS: From the electronic charts of Maccabi Health Services, we identified all patients receiving their first β-blocker treatment between 1998 and 2004, and followed them up, for a diagnosis of Parkinson's disease, between 2005 and 2016. We calculated the morbidity hazard of Parkinson's disease diagnosis in users of β-blockers compared with non-users, as well as users of angiotensin-converting enzyme (ACE) inhibitors for hypertension, after adjusting for sex, age, weight, smoking status, cholesterol levels and use of statins, employing the Cox proportional hazard model. We also conducted a Kaplan-Meier survival analysis. RESULTS: Overall, 145,098 patients received β-blockers, and 1,187,151 patients did not. The adjusted hazard ratio for Parkinson's disease among β-blocker users was 1.51 (95% confidence interval 1.28-1.77; p < 0.0001). In contrast, the Parkinson's disease morbidity hazard for patients receiving ACE inhibitors was no different than for the general population. The morbidity risk showed the effect of cumulative dose response with low threshold levels. CONCLUSIONS: Chronic use of β-blockers confers a time- and dose-dependent increased risk for Parkinson's disease. In view of the available alternatives for β-blockers, their chronic use should be carefully reconsidered.
Authors: M C de Rijk; L J Launer; K Berger; M M Breteler; J F Dartigues; M Baldereschi; L Fratiglioni; A Lobo; J Martinez-Lage; C Trenkwalder; A Hofman Journal: Neurology Date: 2000 Impact factor: 9.910
Authors: Shuchi Mittal; Kjetil Bjørnevik; Doo Soon Im; Adrian Flierl; Xianjun Dong; Joseph J Locascio; Kristine M Abo; Elizabeth Long; Ming Jin; Bing Xu; Yang K Xiang; Jean-Christophe Rochet; Anders Engeland; Patrizia Rizzu; Peter Heutink; Tim Bartels; Dennis J Selkoe; Barbara J Caldarone; Marcie A Glicksman; Vikram Khurana; Birgitt Schüle; David S Park; Trond Riise; Clemens R Scherzer Journal: Science Date: 2017-09-01 Impact factor: 47.728
Authors: Matt Farrer; Jennifer Kachergus; Lysia Forno; Sarah Lincoln; Deng-Shun Wang; Mary Hulihan; Demetrius Maraganore; Katrina Gwinn-Hardy; Zbigniew Wszolek; Dennis Dickson; J William Langston Journal: Ann Neurol Date: 2004-02 Impact factor: 10.422
Authors: Sabina Alexandra Cojocariu; Alexandra Maștaleru; Radu Andy Sascău; Cristian Stătescu; Florin Mitu; Maria Magdalena Leon-Constantin Journal: Medicina (Kaunas) Date: 2021-02-09 Impact factor: 2.430